Streetbeat News

Regulatory

PCSA

Processa Pharmaceuticals shares are trading higher after the company announced FDA clearance of its IND application for a Phase 2 clinical trial of NGC-Cap in breast cancer.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 12:10 pm

PTCT

PTC Therapeutics has submitted a New Drug Application (NDA) to the FDA for Sepiapterin, aimed at treating both pediatric and adult patients with Phenylketonuria (PKU).

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 12:07 pm

PCSA

Processa Pharmaceuticals has received FDA clearance for its IND application to initiate a Phase 2 clinical trial of NGC-Cap in breast cancer. The trial will start this quarter with initial data expected by mid-2025.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 12:07 pm

SCPX

Scorpius Holdings, Inc. (NYSE:SCPX) announced that the NYSE Regulation has withdrawn its delisting determination, and the company's common stock will resume trading on the NYSE American on August 2, 2024.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 12:06 pm

EYEN

Eyenovia, Inc. (NASDAQ:EYEN) and SGN Nanopharma have entered into a collaboration to develop a cyclosporine formulation for chronic dry eye disease using SGN's Micellar Nanoparticle Platform and Eyenovia's Optejet dispenser. The companies are validating the product's manufacturability and plan to consult with the FDA for clinical development.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 12:04 pm

HA

Hawaiian Holdings shares are trading higher after the company disclosed that it reached an agreement with the Department of Justice (DoJ) to extend its review period.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 11:50 am

NTLA

Intellia Therapeutics has received authorization from the UK MHRA to initiate a Phase 1/2 clinical trial of NTLA-3001 for treating Alpha-1 Antitrypsin Deficiency.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 11:41 am

AVXL

Anavex Life Sciences reported promising preclinical results for ANAVEX2-73 (Blarcamesine) in a model of Fragile X Syndrome (FXS), showing potential to address behavioral and cognitive deficits. The company plans to initiate a clinical trial in individuals with FXS.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 11:41 am

NTLA

Intellia Therapeutics has received authorization to initiate a Phase 1/2 clinical trial for NTLA-3001, a treatment for Alpha-1 Antitrypsin Deficiency.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 11:41 am

PEG

Public Service Enterprise Group (PSEG) reaffirmed its FY24 adjusted EPS guidance of $3.60-$3.70, aligning with the $3.67 estimate. The company successfully managed extreme conditions, including a heat wave and a significant earthquake, with minimal disruption. PSEG's regulatory calendar is on track, and the company is set to implement another gas supply cost reduction in October.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 11:35 am